Bispecific antibodies (BsABs) have become a new standard of treatment of refractory/relapsed patients with diffuse large B-cell lymphoma and follicular lymphoma, being also intensively studied in other types of B-cell non-Hodgkin lymphoma (B-NHL). Since the therapy with BsABs results in profound B-cell depletion and T-cell exhaustion, it is associated with significantly increased risk of infections. Additional risk factors involve immune disorders caused by lymphoma itself and previous lines of therapy. In this review, we focus on the infectious complications in B-NHL patients treated BsABs, presenting their incidence in clinical trials, admittedly performed to a large extent during the COVID-19 pandemic, as well as the proposals of infection prophylaxis.
双特异性抗体（BsABs）已成为治疗难治性/复发性弥漫大B细胞淋巴瘤和滤泡性淋巴瘤的新标准疗法，并在其他类型B细胞非霍奇金淋巴瘤（B-NHL）中得到深入研究。由于双特异性抗体治疗会导致显著的B细胞耗竭和T细胞耗竭，其治疗显著增加了感染风险。其他风险因素包括淋巴瘤本身引起的免疫紊乱以及既往治疗史。本综述重点关注接受双特异性抗体治疗的B-NHL患者的感染并发症，介绍其在临床试验中的发生率（需注意这些试验很大程度上是在COVID-19大流行期间进行的），并提出感染预防建议。
肿瘤(癌症)患者之家